Can You Get a GLP-1 Prescription If You've Had Pancreatitis?
Often, yes. As of October 2026, none of the current FDA labels for Wegovy, Zepbound, Foundayo or Saxenda lists a past episode of pancreatitis as a contraindication, so a prior attack does not automatically rule you out. What it does is move the decision from a checkbox to a prescriber's judgment, and that judgment depends heavily on what caused your pancreatitis and whether that cause is still present.
Key takeaways
- The labeled contraindications for these drugs are a personal or family history of medullary thyroid carcinoma (MTC), MEN 2, and serious allergy to the drug. Past pancreatitis is not on that list.
- Every label carries an acute pancreatitis warning and says to stop the drug if pancreatitis is suspected.
- The original 2023 Zepbound label said the drug had not been studied in people with prior pancreatitis. The current August 2026 label no longer contains that sentence.
- Prescribers usually weigh the cause: a gallstone episode treated with gallbladder removal looks very different from recurrent, alcohol-related, or unexplained pancreatitis.
- Bring records. A discharge summary, lab results, imaging and the documented cause make an in-person or telehealth review far more useful.
What the FDA labels actually say
Intake forms ask about pancreatitis because every GLP-1 label has a warning about it. The Wegovy label (revised June 2026) puts it this way:
Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including WEGOVY.
The same section tells prescribers to watch for persistent or severe abdominal pain, sometimes radiating to the back, and to discontinue Wegovy if pancreatitis is suspected. The Zepbound label (revised August 2026), the Foundayo label (revised July 2026) and the Saxenda label carry similar warnings with the same instruction to stop if pancreatitis is suspected.
What none of them does is list prior pancreatitis under Contraindications. For Wegovy, the contraindications are a personal or family history of MTC, MEN 2, and a prior serious hypersensitivity reaction to semaglutide or the product's ingredients. Foundayo's list is the same in substance.
Trial numbers the labels report
The labels report how often pancreatitis and gallbladder problems showed up in the weight-management trials. These figures describe trial populations as a whole. The labels do not report a separate rate for people who had pancreatitis before, so they can't tell you your personal risk.
| Drug (label date) | Pancreatitis in weight trials | Gallbladder findings | Prior pancreatitis a contraindication? |
|---|---|---|---|
| Wegovy (June 2026) | Adjudication-confirmed in 4 Wegovy patients (0.2 per 100 patient-years) vs. 1 on placebo (under 0.1) | Gallstones 1.6% vs. 0.7% (injection), 2.5% vs. 1% (tablet); cholecystitis 0.6% vs. 0.2% | No |
| Zepbound (Aug 2026) | 0.2% on Zepbound vs. 0.2% on placebo in weight trials; 0.84 vs. 0 per 100 patient-years in sleep apnea trials | Gallstones 1.1% vs. 1%; cholecystitis 0.7% vs. 0.2%; gallbladder removal 0.2% vs. 0% | No |
| Foundayo (July 2026) | 6 Foundayo patients (0.14 per 100 patient-years of exposure) vs. 1 on placebo (0.04) | Gallstones 1% vs. 0.7%; acute cholecystitis 0.4% vs. 0.3% | No |
| Saxenda | 9 of 3,291 patients (0.3%) vs. 2 of 1,843 on placebo (0.1%) | Gallstones 2.2% vs. 0.8%; cholecystitis 0.8% vs. 0.4% | No |
Source: Warnings and Precautions and Adverse Reactions sections of the current FDA labels on DailyMed for Wegovy, Zepbound, Foundayo and Saxenda, accessed October 2026.
The wording changed, and that matters for intake forms
When Zepbound was first approved, its 2023 label said: "ZEPBOUND has not been studied in patients with a prior history of pancreatitis. It is unknown if patients with a history of pancreatitis are at higher risk for development of pancreatitis on ZEPBOUND." It also said that if pancreatitis was confirmed, the drug should not be restarted.
The current Zepbound, Wegovy, Saxenda and Foundayo labels do not contain the "not studied" sentence. The labels don't explain the change, so don't read it as proof that a history of pancreatitis is now considered safe. It does mean that some intake questionnaires, which were often written around the older wording, may be stricter than the current label text.
How prescribers think about a past episode
A prior attack is a starting point for questions, not an answer. Most clinicians will want to know four things.
- What caused it. The NIDDK says gallstones are the most common cause of acute pancreatitis, followed by heavy alcohol use, genetic disorders and some medicines. A StatPearls review on NCBI Bookshelf (updated August 2025) puts gallstones at about 35% to 40% of US cases and alcohol at about 17% to 25%, and notes that triglyceride-induced pancreatitis usually involves levels above 1,000 mg/dL.
- Whether the cause has been dealt with. A gallstone episode followed by gallbladder removal, or a triglyceride episode now controlled with treatment, is a different conversation than ongoing heavy drinking or an episode no one could explain.
- How many episodes and how severe. One mild episode years ago differs from recurrent attacks, necrotizing pancreatitis, or a chronic pancreatitis diagnosis.
- How recent. An episode last month calls for more caution and usually more workup than one a decade ago.
Gallbladder history overlaps here. Because the labels link GLP-1 treatment with more gallstones and cholecystitis, and because gallstones are the leading cause of acute pancreatitis, prescribers often ask about both together. Tell them if you've had your gallbladder removed, have known gallstones, or have had gallbladder attacks.
Talk it through with a licensed prescriber
Only a licensed clinician who reviews your history can decide whether a GLP-1 is appropriate; confirm pricing and terms with any provider directly (we may earn a commission if you use this link).
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
Telehealth vs. in-person: which route fits your history
Many online weight-management services screen with a questionnaire before a clinician reviews the file. A "yes" to pancreatitis commonly triggers either a decline or a request for more information. That isn't a judgment on you. It reflects that a form-based visit can't easily sort a single resolved gallstone episode from recurrent disease.
| Your situation | Telehealth review may be reasonable | In-person evaluation usually makes more sense |
|---|---|---|
| Single episode, cause identified and treated (for example, gallbladder removed) | Yes, if you can upload records | Optional |
| Single episode, cause never identified | Less likely | Yes, often with your primary care doctor or a GI specialist |
| Two or more episodes, or chronic pancreatitis | Unlikely | Yes, ideally with gastroenterology input |
| Episode within the past several months | Unlikely | Yes |
| Alcohol-related episode with ongoing drinking, or triglycerides not yet controlled | Unlikely | Yes |
This table summarizes general considerations, not a clinical rule. The labels cited above do not define these categories; your prescriber makes the call.
If you already have a primary care doctor or gastroenterologist who treated the episode, starting there is often faster than it sounds. They have the records, can check current labs, and can document why they consider a GLP-1 reasonable, which also helps if your insurer requires prior authorization.
Records to gather before the visit
Whether you go online or in person, the review goes better when the facts are on paper. Request these from the hospital or clinic patient portal:
- Hospital discharge summary from each episode, which usually states the suspected cause.
- Lab results from the episode, such as lipase or amylase, liver tests, and a triglyceride level.
- Imaging reports (ultrasound, CT or MRI), especially anything describing gallstones or pancreatic changes.
- Surgical notes if you had your gallbladder removed or an ERCP procedure.
- Recent labs, including a current triglyceride level if that was the cause.
- Specialist notes from gastroenterology, if you saw one, including any statement about recurrence risk.
- A current medication list, since the StatPearls review lists several medicines that can cause pancreatitis.
Answer intake questions accurately and attach records when the form allows it. A clear history gives a prescriber something to work with. An omitted one removes the safety check the question exists for.
What's known, and what isn't
Questions about incretin drugs and the pancreas are not new. In March 2013 the FDA issued a drug safety communication saying it was evaluating unpublished findings on pancreatitis and pre-cancerous cell changes in a small number of tissue samples. At the time the agency said it had "not reached any new conclusions about safety risks" and had not concluded the drugs cause or contribute to pancreatic cancer.
The trial data in today's labels show pancreatitis was uncommon across study populations, but the labels give no separate estimate for people who had pancreatitis before starting treatment. That gap is exactly why prescribers individualize this decision rather than applying a blanket yes or no.
Practical next steps
- Pull your records from the episode, using the list above.
- Decide on the route. If your history is a single, explained, resolved episode, a telehealth review with uploaded records may work. Otherwise, start with your primary care doctor or GI specialist.
- Ask the prescriber directly how your specific history affects their recommendation, and whether they'd suggest any labs first.
- If a GLP-1 isn't recommended, ask what alternatives fit your history. There are non-GLP-1 options approved for weight management, each with its own label considerations.
Ready to have your history reviewed?
A licensed prescriber decides whether any medication is appropriate for you; check current pricing and terms with the provider before you pay (we may earn a commission from this link).
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
Frequently asked questions
Is a history of pancreatitis a contraindication for Wegovy or Zepbound?
Not on the current FDA labels. The labeled contraindications are a personal or family history of medullary thyroid carcinoma, MEN 2, and serious hypersensitivity to the drug. The labels do carry an acute pancreatitis warning, and the prescriber decides whether treatment is appropriate.
Why did my telehealth intake decline me after I said I had pancreatitis?
Form-based screening can't easily tell a single resolved gallstone episode from recurrent or unexplained pancreatitis, so many questionnaires decline or ask for more information. An in-person or records-based review with your own doctor or a GI specialist is often the better route.
Does the cause of my pancreatitis matter?
Yes. Prescribers usually ask whether it was caused by gallstones, alcohol, very high triglycerides or a medicine, and whether that cause has been treated. Recurrent, recent or unexplained episodes generally call for more caution.
What records should I bring?
The hospital discharge summary, lab results such as lipase and triglycerides, imaging reports, any gallbladder surgery or ERCP notes, gastroenterology notes, and a current medication list.
What should I do if I get abdominal pain on a GLP-1?
The labels describe pancreatitis as persistent or severe abdominal pain that may spread to the back, with or without nausea or vomiting, and say to stop the drug if pancreatitis is suspected. Seek medical care promptly and tell the clinician what you take.
Sources
- DailyMed: Wegovy (semaglutide) injection and tablet prescribing information, revised June 2026
- DailyMed: Zepbound (tirzepatide) prescribing information, revised August 2026
- DailyMed: Foundayo (orforglipron) prescribing information, revised July 2026
- DailyMed: Saxenda (liraglutide) prescribing information
- FDA: Zepbound original prescribing information (2023)
- NIDDK: Symptoms and causes of pancreatitis
- StatPearls (NCBI Bookshelf): Acute Pancreatitis, updated August 2025
- FDA Drug Safety Communication: Reports of possible increased risk of pancreatitis and pre-cancerous findings (March 14, 2013)
Medical disclaimer: This article is general information, not medical advice, and does not replace a licensed clinician who knows your history. Approvals, labels, coverage and prices change; check the linked sources and talk with your prescriber or pharmacist before making decisions about any medication.